Article in Stroke, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
29 authors.
Takahiko ImaiDepartment of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (T.I., A.L.d.M., X.J., T.Q., J.B.M., C.A.).ORCID 0000-0002-4422-2946
Andreia Lopes de MoraisDepartment of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (T.I., A.L.d.M., X.J., T.Q., J.B.M., C.A.).ORCID 0000-0002-9351-2552
Xuyan JinDepartment of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (T.I., A.L.d.M., X.J., T.Q., J.B.M., C.A.).ORCID 0009-0003-1923-4923
Tao QinDepartment of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (T.I., A.L.d.M., X.J., T.Q., J.B.M., C.A.).
Jessica LambDepartment of Neurology, Zilkha Neurogenetic Institute, Keck School of Medicine of USC, Los Angeles, CA (J.L., K.A.N., P.D.L.).ORCID 0000-0002-0342-9983
Karisma A NagarkattiDepartment of Neurology, Zilkha Neurogenetic Institute, Keck School of Medicine of USC, Los Angeles, CA (J.L., K.A.N., P.D.L.).ORCID 0009-0007-3526-1365
Mu-Hsun ChenDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (M.-H.C., M.A.D.).ORCID 0000-0002-5111-1582
Ligia S B BoisserandDepartment of Neurology, Yale University School of Medicine, New Haven, CT (L.S.B.B., L.H.S.).ORCID 0000-0002-0058-2894
Rakesh B PatelDivision of Hematology/Oncology, Department of Internal Medicine (R.B.P., M.K., A.K.C.), University of Iowa.ORCID 0000-0001-9727-9738
Mariia KumskovaDivision of Hematology/Oncology, Department of Internal Medicine (R.B.P., M.K., A.K.C.), University of Iowa.ORCID 0000-0002-2477-3011
Anjali ChauhanDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston (A.C., J.A., L.D.M.C.).ORCID 0000-0002-9825-8100
Krishnan M DhandapaniDepartment of Neurosurgery (K.M.D.), Medical College of Georgia, Augusta University.ORCID 0000-0001-7044-1117
Mohammad B KhanDepartment of Neurology (M.B.K., P.K.K., D.C.H.), Medical College of Georgia, Augusta University.ORCID 0000-0001-8231-1256
Pradip K KamatDepartment of Neurology (M.B.K., P.K.K., D.C.H.), Medical College of Georgia, Augusta University.ORCID 0000-0002-0376-2284
Yanrong ShiDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (Y.S., S.C., R.C.K.).ORCID 0000-0002-3144-5569
Suyi CaoDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (Y.S., S.C., R.C.K.).ORCID 0000-0002-0230-1232
Basavaraju G SanganahalliDepartment of Radiology and Biomedical Imaging, Yale University, New Haven, CT (B.G.S.).ORCID 0000-0002-0851-6621
Joseph B MandevilleDepartment of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (T.I., A.L.d.M., X.J., T.Q., J.B.M., C.A.).ORCID 0000-0002-4113-5396
Patrick D LydenDepartment of Neurology, Zilkha Neurogenetic Institute, Keck School of Medicine of USC, Los Angeles, CA (J.L., K.A.N., P.D.L.).ORCID 0000-0001-6170-4042
David C HessDepartment of Neurology (M.B.K., P.K.K., D.C.H.), Medical College of Georgia, Augusta University.ORCID 0000-0002-8345-9153
Enrique C LeiraDepartments of Neurology, Neurosurgery and Epidemiology (E.C.L.), University of Iowa.ORCID 0000-0003-3695-2946
Anil K ChauhanDivision of Hematology/Oncology, Department of Internal Medicine (R.B.P., M.K., A.K.C.), University of Iowa.ORCID 0000-0001-8554-0898
Jaroslaw AronowskiDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston (A.C., J.A., L.D.M.C.).ORCID 0000-0002-9256-7973
Louise D McCulloughDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston (A.C., J.A., L.D.M.C.).ORCID 0000-0002-8050-1686
Raymond C KoehlerDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (Y.S., S.C., R.C.K.).ORCID 0000-0002-5890-9992
Lauren H SansingDepartment of Neurology, Yale University School of Medicine, New Haven, CT (L.S.B.B., L.H.S.).ORCID 0000-0002-6898-1680
Márcio A DinizDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (M.-H.C., M.A.D.).ORCID 0000-0002-2427-7843
Cenk AyataDepartment of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (T.I., A.L.d.M., X.J., T.Q., J.B.M., C.A.).ORCID 0000-0002-3644-6042
SPAN Investigators
Funding
Targeting Pyruvate Kinase M2: A novel strategy to combat thrombo-inflammationR35HL139926 · NHLBI · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR · 2018 to 2024
$5.3M
The NIH SPAN Coordinating CenterU24NS113452 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LYDEN, PATRICK D · 2019 to 2021
$2.4M
Wnt Signaling in StrokeR01NS105894 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOEHLER, RAYMOND CHARLES · 2018 to 2022
$2.3M
Stroke Preclicinal Assessment NetworkU01NS130588 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AYATA, CENK · 2023 to 2025
$1.9M
Microglia/macrophage polarization after intracerebral hemorrhageR01NS102583 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOEHLER, RAYMOND CHARLES · 2018 to 2021
$1.8M
Mechanisms of Chronic Remote Ischemic Conditioning Induced Cerebroprotection in a VCID ModelR01NS099455 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2017 to 2020
$1.5M
Rheoerythrocrine dysfunction in stroke and remote ischemic conditioning (REDS)R01NS112511 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2020 to 2023
$1.3M
Yale site for Stroke Preclinical Assessment Network (SPAN) for Acute NeuroprotectionU01NS113445 · NINDS · YALE UNIVERSITY · PI SANSING, LAUREN H · 2019 to 2021
$1.2M
Multicenter preclinical trial of rho-kinase inhibitor fasudil in acute focal cerebral ischemia and reperfusionU01NS113443 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AYATA, CENK · 2019 to 2021
$1.2M
Stroke Preclinical Assessment Network (SPAN) – Tacilizumab for treatment of acute ischemic strokeU01NS113451 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARONOWSKI, JAROSLAW · 2019 to 2021
$1.1M
The University of Iowa Stroke Preclinical Assessment Center for Neuroprotection in strokeU01NS113388 · NINDS · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR, LEIRA, ENRIQUE CARLOS · 2019 to 2021
$1.1M
Remote Ischemic Conditioning: A collateral therapeutic and neuroprotectantU01NS113356 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2019 to 2021
backgroundThe SPAN (Stroke Preclinical Assessment Network) is a confirmatory multicenter trial network to test cerebroprotective interventions in experimental acute stroke. In a first-of-its-kind trial, SPAN tested 6 interventions in a rodent model of transient focal ischemic stroke. Here, we report the efficacy of fasudil, an isoform-nonselective rho-associated kinase inhibitor, on primary and secondary outcomes in the SPAN trial.
methodsFasudil was administered at 10 mg/kg intraperitoneally every 12 hours for 6 doses starting 5 minutes before reperfusion in a 60-minute endovascular filament middle cerebral artery occlusion model. The active treatment arm (n=345) was compared with the pooled intraperitoneal and intravenous vehicle arms (n=344). In addition to healthy young mice, the trial included aging mice (16±1 months), diet-induced obese mice, and spontaneously hypertensive rats. The a priori fasudil substudy design stipulated the modified corner test performance on day 28 as the primary end point and separate analyses for mice and spontaneously hypertensive rats using the modified intention-to-treat cohort.
resultsFasudil improved the primary outcome end point in mice (probabilistic index point estimate, 0.57;
conclusionsOur results reveal a favorable therapeutic profile for fasudil, supporting future translational development of rho-associated kinase inhibitors in ischemic stroke.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Multicenter SPAN Trial of Fasudil in Ischemic Stroke. · full record | OpenQuestion